

Resource Summary Report

Generated by T1D on Aug 10, 2026

Uppsala Monitoring Centre; Uppsala; Sweden

RRID:SCR_026434

Type: Tool

Proper Citation

Uppsala Monitoring Centre; Uppsala; Sweden (RRID:SCR_026434)

Resource Information

URL: <https://who-umc.org/>

Proper Citation: Uppsala Monitoring Centre; Uppsala; Sweden (RRID:SCR_026434)

Description: Uppsala Monitoring Centre, located in Uppsala, Sweden, is the field name for the World Health Organization Collaborating Centre for International Drug Monitoring. UMC works by collecting, assessing and communicating information from member countries' national pharmacovigilance centres in regard to benefits, harm, effectiveness and risks of drugs since 1978.

Abbreviations: UMC

Resource Type: nonprofit organization

Keywords: World Health Organization Collaborating Centre for International Drug Monitoring, drugs, collecting, assessing, communicating information, benefits, harm, effectiveness, risks

Resource Name: Uppsala Monitoring Centre; Uppsala; Sweden

Resource ID: SCR_026434

Alternate IDs: , ISNI: 0000 0001 2153 0703, GRID: grid.420224.2, Wikidata: Q7899169

Alternate URLs: <https://ror.org/057rhqk62>

Record Creation Time: 20250219T060352+0000

Record Last Update: 20260808T190742+0000

Ratings and Alerts

No rating or validation information has been found for Uppsala Monitoring Centre; Uppsala; Sweden.

No alerts have been found for Uppsala Monitoring Centre; Uppsala; Sweden.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Duboëlle M, et al. (2026) JAK Inhibitors and Memory Impairment: Disproportionality Analyses in the WHO Global Pharmacovigilance Database, VigiBase. *Fundamental & clinical pharmacology*, 40(1), e70072.

Xie Y, et al. (2025) Drug-induced Sweet's syndrome: pharmacovigilance insights from FAERS with a cross-database consistency assessment in VigiBase via LASSO and multivariable logistic regression. *Frontiers in immunology*, 16, 1622736.

Tan Y, et al. (2025) Comparison of ileus risk in selected second-generation antipsychotics based on FAERS database. *Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society*, 33(3), 13.

Park S, et al. (2025) Neurological Adverse Events Associated with the Use of Janus Kinase Inhibitors: A Pharmacovigilance Study Based on Vigibase. *Pharmaceuticals (Basel, Switzerland)*, 18(3).

Wang L, et al. (2025) Real world pharmacovigilance comparison of viloxazine and dextroamphetamine adverse reaction profiles. *Scientific reports*, 15(1), 28919.

Di Napoli R, et al. (2025) Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database. *Drug safety*, 48(8), 943.

Sun J, et al. (2025) Association of medication regimen complexity index with ADRs in HIV/AIDS patients: a retrospective cohort study. *Frontiers in pharmacology*, 16, 1721289.

Macías Saint-Gerons D, et al. (2023) Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase. *Drugs - real world outcomes*, 10(2), 263.

Park G, et al. (2022) A tree-based scan statistic for zero-inflated count data in post-market drug safety surveillance. *Scientific reports*, 12(1), 16299.

Esan OT, et al. (2022) Directly observed and reported respectful maternity care received during childbirth in public health facilities, Ibadan Metropolis, Nigeria. *PloS one*, 17(10), e0276346.